Vitamin E and selenium are the two most popular dietary supplements used to prevent prostate cancer. The hypothesis that these antioxidants reduce prostate risk is being tested in the selenium and vitamin E chemoprevention trial (SELECT). We hypothesize that selenium potentiates vitamin E-induced inhibition of prostate cancer cell growth in vitro. Prostate cancer cell populations growing asynchronously were treated with a combination of vitamin E and selenium and processed for flow cytometric analysis. Prostate cancer cells treated with a combination of the antioxidants revealed that selenium potentiates vitamin Einduced inhibition of LNCaP cells in vitro. This was demonstrated by a reduction in the percentage of cells in the S phase. This crucial finding confirms our previous observations that antioxidant molecules act via distinct mechanistic pathways. These independent biological effects can be exploited in order to augment the anticancer properties of individual agents. These data also validate the two factorial design of the SELECT trial, permitting pairwise comparisons between agents in combination and alone.
Introduction
Clinical and epidemiological evidence suggests that the progression of prostate cancer from microfoci to clinical disease is preventable. Recent clinical studies have indicated that selenium and vitamin E are promising candidates for prostate cancer prevention. The observations are based on secondary analysis of large chemoprevention trials in other cancers. 1, 2 To test the hypothesis that these micronutrients have a preventive effect on prostate cancer, a large-scale clinical trial of selenium and vitamin E (SELECT) has been initiated recently. This is an international phase III, randomized, double-blind, placebo-controlled trial, designed to test the efficacy of selenium and vitamin E alone and in combination. While the clinical interest in the use of vitamin E and selenium together is widespread, there have been no laboratory studies of the potential synergistic effects of vitamin E and selenium.
Selenium is a nonmetallic trace element essential to human health and has been shown to inhibit tumorigenesis in various experimental models. 3 We have shown that selenium inhibits the growth of the androgensensitive human prostate cancer cell line LNCaP but not that of the androgen-independent PC3. Transfection of the androgen receptor resulted in the inhibition of cell proliferation accompanied by cell cycle arrest. This suggests that selenium requires a functional androgen receptor to induce arrest. 4 Vitamin E (a-tocopherol) belongs to a family of naturally occurring, essential fat-soluble vitamins. These function as lipid-soluble antioxidants in cell membranes, and as free radical scavengers that inhibit lipid peroxidation.
5 a-Tocopherol may influence cancer development through several mechanisms. It has been shown to inhibit the growth of several human cancer cell lines including prostate. 6 We have shown that vitamin E induces growth arrest in prostate cancer cell lines mediated by alterations in cell cycle regulatory proteins, particularly p27 Kipl . 7 We have extended our study to determine the interaction between vitamin E and selenium in prostate cancer cell lines.
Materials and methods
Two established human prostate cancer cell lines were used. LNCaP (androgen responsive) and PC3 (androgen independent) were obtained from the American Type Culture Collection (Rockville, MD, USA). LNCaP cells were cultured in RPMI 1640 medium with L-glutamine (Gibco BRL, Grand Island, NY, USA), supplemented with 10% fetal bovine serum (FBS) and 100 IU/ml penicillin and 100 mg/ml streptomycin. PC3 was cultured in DMEM/F12 medium with 10% FBS and antibiotics. Cells were maintained at 371C in a humidified atmosphere of 5% CO 2 in air, grown to 80% confluence in 10 cm tissue culture plates and split 1 : 8. Cell populations growing asynchronously were treated with the antioxidants. Controls received the vehicle alone. Treatment was started after 24 h of attachment. The cells were incubated in culture for a maximum of 72 h prior to recovery for flow cytometry and protein analysis. Vitamin E (a-tocopherol succinate) was reconstituted in 95% ethanol and selenium (seleno-DL-methionine) in 0.005 N HCl. Based on previous work, these were added to the cultures at a concentration of 20 mg/ml and 150 mM, respectively. 4, 7 Asynchronously growing cells were pulse labeled with 10 mM bromodeoxyuridine (BrdU) for 2 h with or without prior treatment of the antioxidants. Cells were harvested, fixed with 70% ethanol, treated with 0.1% HCl and heated for 10 min at 901C to expose the labeled DNA. Cells were stained with anti-BrdU-conjugated FITC (Becton-Dickinson) and counterstained with propidium iodide. Cell cycle analysis was carried out on a Becton-Dickinson FACScan, using Lysis II software.
Since this study focused on the synergistic effects of vitamin E and selenium in prostate cancer cell lines, nonprostate cancer lines were not included in the experiments.
Results
LNCaP and PC3 cells were treated with optimized doses of a combination of vitamin E and selenium. With the combination of the antioxidants, LNCaP cells exhibited a G1 arrest (Figure 1) , with a 93.9% reduction in the S phase (Table 1 ). This was a substantially greater degree of arrest than was seen with either of the antioxidants alone. LNCaP cells individually treated with vitamin E or selenium resulted in a 47.3 and 80.3% reduction in the S phase, respectively ( Table 1 ). The synergistic effect of vitamin E and selenium was seen as early as 48 h of treatment with an 83.5% reduction in S phase, on the androgen-dependent LNCaP. PC3 cells treated with a combination of vitamin E and selenium demonstrated no substantial alteration in the reduction in the S phase at the end of 72 h of treatment (Table 1) . We have shown that selenium inhibits the growth of the androgensensitive human prostate cancer cell line LNCaP but not that of the androgen-independent PC3 cell line. 4 
Discussion
Chemoprevention trials are based upon biological or epidemiological evidence that agents, such as micronutrients, can significantly inhibit carcinogenic pathways. [8] [9] [10] [11] [12] [13] In the context of prostate cancer, relatively little biological evidence supported the study of micronutrients. In contrast, it was the non-a priori-determined end points from prior intervention studies that led to the concepts of using vitamin E and selenium in prostate cancer prevention (SELECT trial). Recently, significant biological effects of these agents in prostate cancer model systems have been demonstrated. 4, 7 The novel finding of this study is that selenium potentiates vitamin E-induced inhibition of androgensensitive prostate cancer cell growth in vitro. This crucial finding confirms our previous observations that antioxidant molecules act via distinct mechanistic pathways. 4, 7 Interestingly, vitamin E had a more pronounced effect on cell cycle inhibition in PC-3 than LNCaP, while selenium alone induced arrest only in LNCaP. This provides further indirect evidence that these micronutrients are acting via different pathways. These independent biological effects can be exploited in order to augment the anticancer properties of individual agents. [8] [9] [10] [11] [12] [13] These data also validate the two factorial design of the SELECT trial, which will permit pairwise comparisons between these agents in combination and alone. Synergistic effect of vitamin E and selenium V Venkateswaran et al
